Clinical trials: Bone Diseases, Endocrine
Achondroplasia
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
- Trial name
- NCT03424018
- Testing
- BMN 111
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 119 people
- Sponsor
- BioMarin Pharmaceutical
Loss of Chromosome 18q, Growth Hormone Deficiency
Growth Hormone and Chromosome 18q- and Abnormal Growth
We, the investigators at the University of Texas Health Science Center at San Antonio, want to learn if height and IQ (intelligence quotient) scores are improved by growth hormone (GH) treatment in children with chromosome 18…
- Trial name
- NCT00134420
- Testing
- Nutropin AQ, Arginine and Clonidine Stimulation Testing, Growth Factors Laboratory Testing
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cancer
Tissue Study of Bv8/PK-2 Inhibition in Human Cancer
Study hypothesis is that inhibition of Bv8 production in bone marrow cells of a mice wil reduce the rate of growth of a primary human tumor implanted in the mice.
- Trial name
- NCT01656824
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rambam Health Care Campus
Healthy, Adult
Understanding Effects of Calcium on the Gut-Bone Axis
The study team is inviting 13 healthy people to complete a study to explore how calcium affects hormones and bones after eating. Participants will be asked to complete two study visits within eight weeks.
- Conditions
- Healthy, Adult, Calcium, Bone Resorption
- Trial name
- NCT06383117
- Testing
- Calcium carbonate
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- University of Georgia
Acromegaly, Osteoporosis Risk
Bone MicroArchitecture in Acromegaly
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH)…
- Trial name
- NCT03225040
- Testing
- Pegvisomant
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Columbia University
Quality of Life, Acromegaly
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
Study Synopsis Study Title: Double blind, single centre, cross-over study on the effects of weekly subcutaneous administration of 40 mg pegvisomant or placebo on quality of life and insulin sensitivity in acromegalic patients…
- Trial name
- mec-2005-290 (NCT00642720)
- Testing
- Pegvisomant
- Volunteers
- 20 people
- Sponsor
- Erasmus Medical Center
Exophthalmos, Graves Ophthalmopathy
Exophthalmometry With 3D Face Scanners
This study investigates diagnostic methods to measure eyeball protrusion with a smartphone face scanner compared to the traditional Hertel exophthalmometer.
- Conditions
- Exophthalmos, Graves Ophthalmopathy, Orbital Tumor, Orbital Fractures
- Trial name
- EX3D (NCT04704414)
- Testing
- Exophthalmos measurement
- Where
- Switzerland
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Acromegaly Cardiomyopathy
Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy
Pathophysiology of acromegaly cardiomyopathy is yet unclear and a specific treatment have not been indicated. It was already demonstrated the positive impact of phosphodiesterase type 5A (PDE5A) inhibition in several models of…
- Trial name
- SUM (NCT02611336)
- Testing
- Tadalafil
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- Andrea M. Isidori
Adult Growth Hormone Deficiency (AGHD)
A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)
The GS3-007a Growth Hormone Stimulation Test (GHST) will be compared with the Insulin Tolerance Test (ITT) in an open-label, randomized, three-way crossover trial.
- Trial name
- NCT07259564
- Testing
- GS3-007a dry suspension, Insulin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Acromegaly
Acromegaly: Balance, Falls and Fracture Risk
The goal of this observational, cross-sectional study is to study bone quality, joint quality and fall risk in acromegalic patients, compared with healthy controls.
- Trial name
- NCT05752825
- Testing
- HR-pQCT, DXA scan, Bone microindentation
- Where
- Denmark
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Christian Alexander H Rosendal
Acromegaly
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly
The purpose of the protocol is evaluate the safety, the pharmacodynamics and the pharmacokinetic of repeated administration of BIM23B065 in subjects with acromegaly.
- Trial name
- DOPAACRO 002 (NCT03045302)
- Testing
- BIM23B065
- Where
- 6 sites in Belgium, Hungary and 2 more
- Volunteers
- 4 people
- Sponsor
- Ipsen
Hypoparathyroidism, Cardiovascular Complication
Cardiovascular, Renal, and Skeletal Complications in Patients With Post-Surgical Hypoparathyroidism
The aim of this observational study is to learn about long term effects to post surgical hypoparathyroidism. The main questions are: 1.
- Conditions
- Hypoparathyroidism, Cardiovascular Complication, Fractures, Bone, Renal Disease
- Trial name
- CAREHYPO (NCT06419270)
- Testing
- Observation
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Healthy, Osteoporosis
Hormone Replacement in Young Women With Premature Ovarian Failure
The human ovary produces male sex hormones (androgen) and female sex hormones (estrogen). Currently, androgen is not included in hormone replacement therapy for women with premature ovarian failure.
- Conditions
- Healthy, Osteoporosis, Premature Ovarian Failure
- Trial name
- NCT00001951
- Testing
- TMTDS
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Growth Hormone Deficiency
Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)
This is a multi-national trial. The goals of the trial are to study LUM-201 as a possible treatment for Pediatric Growth Hormone Deficiency (PGHD) and investigate a predictive enrichment marker (PEM) strategy to select subjects…
- Trial name
- OraGrowtH210 (NCT04614337)
- Testing
- LUM-201, rhGH Norditropin® pen (34 µg/kg)
- Where
- 43 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Lumos Pharma
Acromegaly
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
A multicentre, prospective, open label study of acromegalic patients evaluating the efficacy and safety of different dose-intervals of Lanreotide Autogel 120mg according to international standards and compared to previous…
- Trial name
- NCT00444873
- Testing
- lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Ipsen
Congenital Hypothyroidism
Quality of Life and Long-term Outcome of Adequately Treated Congenital Hypothyroidism
The primary objective of this observational study is the evaluation of the quality of life and long-term outccome of young-adult patients with congenital hypothyroidism diagnosed by neonatal screening receiving replacement…
- Trial name
- CHQoL (NCT06864039)
- Testing
- SF36 test, WAIS IV test, SCL-90 psychopathological screening questionnaire
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Federico II University
Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses…
- Trial name
- HCH (NCT06873035)
- Testing
- infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 24 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Diabetes Mellitus, Type 2, Bone Fragile
Bone Turnover in Type 2 Diabetes and Non-diabetes Controls (DiaMarv)
Type 2 diabetes (T2D) is related to an increased risk of major fractures which does written in English. The summary is used not only increase society health care costs, but also increase the morbidity and in the recruitment of…
- Trial name
- DiaMarv (NCT05585697)
- Testing
- None - crossectional
- Where
- Denmark
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Osteoporosis, Chronic Kidney Disease Mineral and Bone Disorder
Osteoporosis & Renal Disease: Research in Primary Health Care Services
Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures.
- Trial name
- NCT07848490
- Testing
- Fracture risk assessment tool (FRAX), Dual-Energy X-ray Absorptiometry (DXA)
- Where
- Portugal
- Volunteers
- 622 people
- Sponsor
- Universidade do Porto
Type 2 Diabetes, Hip Fractures
Retrospective Study: Hip Fractures in Diabetic Patients
Type 2 DM patients are at increased risk of falls as a consequence of long term hyperglycemic complications including retinopathy and neuropathy, and also as a result of hypoglycaemic therapy.
- Trial name
- NCT01379690
- Testing
- HBA1C
- Where
- Singapore
- Volunteers
- 1,162 people
- Sponsor
- Changi General Hospital